Novartis’ Post

Chronic myeloid leukemia (CML) is a type of cancer that affects the blood and bone marrow, where blood cells are made. Recognizing the symptoms of CML is crucial for early detection. These can include fatigue, weight loss, fever, and an enlarged spleen causing discomfort on the left side of the abdomen. Taking proactive steps with your healthcare provider for regular check-ups and monitoring can be beneficial, leading to better disease management and improved quality of life (#QoL). Learn more about CML and its management here: https://lnkd.in/gVRjQiAy

At #EHA24, we are proud to present data from our Phase III ASC4FIRST trial for patients with newly diagnosed chronic myeloid leukemia (#CML). CML is a type of cancer that develops in the blood-forming cells of the bone marrow. Despite 25 years of innovation in CML, unmet needs still exist as newly diagnosed patients may fail to meet molecular response goals or discontinue or change treatments due to intolerance. Learn more about Novartis commitment to fighting blood cancers: https://lnkd.in/gvzPZJiQ

Paroxysmal nocturnal hemoglobinuria (PNH) is a debilitating blood disorder which causes a range of life-limiting symptoms for those affected. We spoke to the Aplastic Anemia and MDS International Foundation (AAMDSIF) to highlight the importance of providing support for patients living with rare diseases Click the link to learn more about AAMDSIF and the strides they are making to improve life for people living with PNH: https://lnkd.in/gZUvmp-T

We are proud to share that our study investigating #radioligandtherapy has been selected as Abstract of the Year by Society of Nuclear Medicine and Molecular Imaging (SNMMI), reinforcing its potential for patients in need. #ReimagineMedicine #SNMMI24

At Novartis, our long-standing commitment to patients living with chronic myeloid leukemia (CML) spans more than two decades, marked by breakthroughs that have helped turn what was once a life-limiting condition into a chronic one for many. Yet, there's more ground to cover. Despite advancements, many patients still face hurdles such as lower response rates, treatment resistance, and intolerance, and have poor quality of life. That’s why we’re committed to continuing to pioneer targeted treatments for CML, and ensuring every patient has access to innovative medicines. Learn more here: https://lnkd.in/gadSYVJg

This #EHA24, we are delighted to be sharing new data in paroxysmal nocturnal hemoglobinuria (PNH) - a rare and serious blood disorder. Learn more about our commitment to patients living with PNH: https://lnkd.in/g7_yemU7

At Novartis, we're committed to reimagining the future of cancer care. At the heart of our mission lies a commitment to revolutionizing cancer care by addressing the pressing unmet needs of patients living with diverse types of cancer. With a broad oncology portfolio, we are dedicated to addressing these needs and developing innovative therapies that bring hope to patients and their loved ones. By exploring innovative therapies, we're pioneering new standards of care for patients worldwide. Learn more here: https://lnkd.in/gHheFZFp

This Pride Month, we want to spotlight the impact of our Pride Employee Resource Groups, who play a critical role in connecting and supporting our global LGBTQI and ally community at Novartis. By providing a safe space to share lived experiences, they help spark ideas that create positive change for our people and patients. Through these grassroots efforts and ongoing collaborations with organizations such as Stonewall and myGwork - LGBTQ Business Community, we are committed to driving LGBTQI equity and inclusion together. To find out more about LGBTQI Equity at Novartis, visit: https://lnkd.in/g9WxcSPK #PRIDE2024 #ThriveTogether

Collaboration with the patient community and medical experts is paramount in enabling our continued innovation for cancer patients with #Radioligandtherapy (RLT). #ASCO24